Gregory A Nichols

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6014905/publications.pdf

Version: 2024-02-01

94 papers 7,533 citations

37 h-index

94433

85 g-index

96 all docs 96 docs citations

96 times ranked 10122 citing authors

#	Article	IF	CITATIONS
1	Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization. Archives of Internal Medicine, 2004, 164, 659.	3.8	1,394
2	Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 2010, 87, 293-301.	2.8	858
3	The Incidence of Congestive Heart Failure in Type 2 Diabetes. Diabetes Care, 2004, 27, 1879-1884.	8.6	685
4	The Burden of Treatment Failure in Type 2 Diabetes. Diabetes Care, 2004, 27, 1535-1540.	8.6	406
5	Progression From Newly Acquired Impaired Fasting Glusose to Type 2 Diabetes. Diabetes Care, 2007, 30, 228-233.	8.6	219
6	Cost of Medical Care for Chronic Kidney Disease and Comorbidity among Enrollees in a Large HMO Population. Journal of the American Society of Nephrology: JASN, 2004, 15, 1300-1306.	6.1	167
7	Secondary Failure of Metformin Monotherapy in Clinical Practice. Diabetes Care, 2010, 33, 501-506.	8.6	159
8	Does Statin Therapy Initiation Increase the Risk for Myopathy? An Observational Study of 32,225 Diabetic and Nondiabetic Patients. Clinical Therapeutics, 2007, 29, 1761-1770.	2.5	158
9	Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation. Diabetes Care, 2009, 32, 1851-1856.	8.6	158
10	Body Mass Index and Future Healthcare Costs: A Retrospective Cohort Study. Obesity, 2001, 9, 210-218.	4.0	154
11	Unadjusted and Adjusted Prevalence of Diagnosed Depression in Type 2 Diabetes. Diabetes Care, 2003, 26, 744-749.	8.6	136
12	Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis. American Journal of Medicine, 2008, 121, 519-524.	1.5	128
13	Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic Control. Journal of General Internal Medicine, 2007, 22, 453-458.	2.6	125
14	Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005–2011. Diabetes Care, 2016, 39, 363-370.	8.6	121
15	Construction of a Multisite DataLink Using Electronic Health Records for the Identification, Surveillance, Prevention, and Management of Diabetes Mellitus: The SUPREME-DM Project. Preventing Chronic Disease, 2012, 9, E110.	3.4	119
16	Weight Change in Diabetes and Glycemic and Blood Pressure Control. Diabetes Care, 2008, 31, 1960-1965.	8.6	118
17	Trends in Diabetes Incidence Among 7 Million Insured Adults, 2006–2011. American Journal of Epidemiology, 2015, 181, 32-39.	3.4	105
18	Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis International, 2005, 16, 2168-2174.	3.1	99

#	Article	IF	CITATIONS
19	The Impact of Cardiovascular Disease on Medical Care Costs in Subjects With and Without Type 2 Diabetes. Diabetes Care, 2002, 25, 482-486.	8.6	96
20	The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes/Metabolism Research and Reviews, 2005, 21, 51-57.	4.0	92
21	Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statinâ€controlled LDL cholesterol. Diabetes, Obesity and Metabolism, 2019, 21, 366-371.	4.4	90
22	Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization inÂPatients With Heart Failure and Preserved Versus Reduced Ejection Fraction. American Journal of Cardiology, 2015, 116, 1088-1092.	1.6	84
23	Preventable Major Cardiovascular Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids and Active Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A Contemporary Analysis. Diabetes Care, 2015, 38, 905-912.	8.6	83
24	Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3019-3027.	3.6	74
25	Slow response to loss of glycemic control in type 2 diabetes mellitus. American Journal of Managed Care, 2003, 9, 213-7.	1.1	70
26	Treatment Escalation and Rise in HbA1c Following Successful Initial Metformin Therapy. Diabetes Care, 2006, 29, 504-509.	8.6	67
27	The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2014, 28, 10-16.	2.3	67
28	Relation of Acute Heart Failure Hospital Length of Stay to Subsequent Readmission and All-Cause Mortality. American Journal of Cardiology, 2015, 116, 400-405.	1.6	65
29	Glycemic Control and Risk of Cardiovascular Disease Hospitalization and All-Cause Mortality. Journal of the American College of Cardiology, 2013, 62, 121-127.	2.8	62
30	Medical Care Costs Associated With Progression of Diabetic Nephropathy. Diabetes Care, 2011, 34, 2374-2378.	8.6	60
31	Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e001847.	2.8	51
32	Glycemic Response and Attainment of A1C Goals Following Newly Initiated Insulin Therapy for Type 2 Diabetes. Diabetes Care, 2012, 35, 495-497.	8.6	47
33	High rates of severe hypoglycemia among African American patients with diabetes: the surveillance, prevention, and Management of Diabetes Mellitus (SUPREME-DM) network. Journal of Diabetes and Its Complications, 2017, 31, 869-873.	2.3	44
34	Medical care costs among patients with established cardiovascular disease. American Journal of Managed Care, 2010, 16, e86-e93.	1.1	44
35	Higher Medical Care Costs Accompany Impaired Fasting Glucose. Diabetes Care, 2005, 28, 2223-2229.	8.6	43
36	Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Current Medical Research and Opinion, 2010, 26, 2127-2135.	1.9	42

#	Article	IF	CITATIONS
37	Independent Contribution of A1C, Systolic Blood Pressure, and LDL Cholesterol Control to Risk of Cardiovascular Disease Hospitalizations in Type 2 Diabetes: An Observational Cohort Study. Journal of General Internal Medicine, 2013, 28, 691-697.	2.6	42
38	Insomnia is associated with an increased risk of type 2 diabetes in the clinical setting. BMJ Open Diabetes Research and Care, 2018, 6, e000604.	2.8	39
39	Health Care System-level Factors Associated With Performance on Medicare STAR Adherence Metrics in a Large, Integrated Delivery System. Medical Care, 2015, 53, 332-337.	2.4	38
40	Predicting the 6-month risk of severe hypoglycemia among adults with diabetes: Development and external validation of a prediction model. Journal of Diabetes and Its Complications, 2017, 31, 1158-1163.	2.3	37
41	Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes and Endocrinology,the, 2022, 10, 112-119.	11.4	37
42	Metabolic Syndrome Components Are Associated with Future Medical Costs Independent of Cardiovascular Hospitalization and Incident Diabetes. Metabolic Syndrome and Related Disorders, 2011, 9, 127-133.	1.3	36
43	Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREMEâ€DM) study. Pharmacoepidemiology and Drug Safety, 2014, 23, 699-710.	1.9	35
44	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	4.4	33
45	Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure. Journal of the American Society of Nephrology: JASN, 2020, 31, 1594-1601.	6.1	33
46	The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 291-297.	2.3	31
47	All Major Serum Lipoproteins After Initiation of Lipid Altering Therapyâ€â€Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis	1.6	29
48	Pharmaceuticals Corporation, Eas. American Journal of Cardiology, 2009, 104, 1689-1694. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1587-1591.	2.3	28
49	Cardiometabolic Risk Factors Among 1.3 Million Adults With Overweight or Obesity, but Not Diabetes, in 10 Geographically Diverse Regions of the United States, 2012–2013. Preventing Chronic Disease, 2017, 14, E22.	3.4	28
50	Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. American Heart Journal, 2007, 154, 554-560.	2.7	24
51	Prescription medication burden in patients with newly diagnosed diabetes: A SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 374-382.	1.5	24
52	Weight Change and Glycemic Control After Diagnosis of Type 2 Diabetes. Journal of General Internal Medicine, 2008, 23, 1339-1345.	2.6	23
53	Medical Care Costs One Year After Identification of Hyperglycemia Below the Threshold for Diabetes. Medical Care, 2008, 46, 287-292.	2.4	22
54	Methods for engaging stakeholders in comparative effectiveness research: A patient-centered approach to improving diabetes care. Healthcare, 2015, 3, 80-88.	1.3	22

#	Article	IF	CITATIONS
55	Patient Characteristics and Medical Care Costs Associated With Hypertriglyceridemia. American Journal of Cardiology, 2011, 107, 225-229.	1.6	21
56	Change in High-Density Lipoprotein Cholesterol and Risk of Subsequent Hospitalization for Coronary Artery Disease or Stroke Among Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 1124-1128.	1.6	21
57	Initial Antihyperglycemic Drug Therapy Among 241 327 Adults With Newly Identified Diabetes From 2005 Through 2010. Annals of Pharmacotherapy, 2013, 47, 1280-1291.	1.9	21
58	Who Must We Target Now to Minimize Future Cardiovascular Events and Total Mortality?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 508-516.	2.2	21
59	Diabetes incidence for all possible combinations of metabolic syndrome components. Diabetes Research and Clinical Practice, 2010, 90, 115-121.	2.8	20
60	Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. American Journal of Managed Care, 2008, 14, 791-8.	1.1	20
61	An Innovative Approach to Informing Research: Gathering Perspectives on Diabetes Care Challenges From an Online Patient Community. Interactive Journal of Medical Research, 2015, 4, e13.	1.4	19
62	Contemporary Analysis of Secondary Failure of Successful Sulfonylurea Therapy. Endocrine Practice, 2007, 13, 37-44.	2.1	18
63	Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM Project, 2005–2011. Journal of Diabetes and Its Complications, 2015, 29, 637-643.	2.3	18
64	Medical Care Costs Associated With Long-term Weight Maintenance Versus Weight Gain Among Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1981-1986.	8.6	18
65	A Simple Model for Predicting Two-Year Risk of Diabetes Development in Individuals with Prediabetes. , 2018, 22, 17-050.		18
66	Antihypertensive Drug Class Interactions and Risk for Incident Diabetes: A Nested Case–Control Study. Journal of the American Heart Association, 2013, 2, e000125.	3.7	17
67	Diabetes care and outcomes for American Indians and Alaska natives in commercial integrated delivery systems: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) Study. BMJ Open Diabetes Research and Care, 2014, 2, e000043.	2.8	16
68	Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrology, 2020, 21, 167.	1.8	16
69	Effect of a patient panel-support tool on care delivery. American Journal of Managed Care, 2010, 16, e256-66.	1.1	16
70	The High Prevalence of Diabetes in a Large Cohort of Patients Drawn From Safety Net Clinics. Preventing Chronic Disease, 2016, 13, E78.	3.4	15
71	Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. Current Medical Research and Opinion, 2010, 26, 9-15.	1.9	14
72	The Association Between Different A1C-Based Measures of Glycemia and Risk of Cardiovascular Disease Hospitalization. Diabetes Care, 2014, 37, 167-172.	8.6	14

#	Article	IF	CITATIONS
73	Validating the Framingham Offspring Study equations for predicting incident diabetes mellitus. American Journal of Managed Care, 2008, 14, 574-80.	1.1	14
74	Medicare Star excludes diabetes patients with poor CVD risk factor control. American Journal of Managed Care, 2014, 20, e573-81.	1.1	12
75	Provider beliefs about diabetes treatment have little impact on glycemic control of their patients with diabetes. BMJ Open Diabetes Research and Care, 2015, 3, e000062.	2.8	11
76	The Patient Outcomes Research To Advance Learning (PORTAL) Network Adult Overweight and Obesity Cohort: Development and Description. JMIR Research Protocols, 2016, 5, e87.	1.0	11
77	The incidence of heart failure among nondiabetic patients with and without impaired fasting glucose. Journal of Diabetes and Its Complications, 2009, 23, 224-228.	2.3	10
78	The Change in HbA1c Associated with Initial Adherence and Subsequent Change in Adherence among Diabetes Patients Newly Initiating Metformin Therapy. Journal of Diabetes Research, 2016, 2016, 1-5.	2.3	10
79	Comparison of Medical Care Utilization and Costs Among Patients With Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia. American Journal of Cardiology, 2018, 122, 1128-1132.	1.6	10
80	Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes. Pharmacotherapy, 2017, 37, 1204-1214.	2.6	9
81	The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: A retrospective chart review involving up to 8 years of follow-up. Clinical Therapeutics, 2006, 28, 243-250.	2.5	8
82	Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2012, 6, 443-449.	1.5	8
83	Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2017, 119, 410-415.	1.6	8
84	Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 727-734.	4.5	7
85	Predictors of Hyperkalemia and Hypokalemia in Individuals with Diabetes: a Classification and Regression Tree Analysis. Journal of General Internal Medicine, 2020, 35, 2321-2328.	2.6	6
86	Comparison of Evidence-Based Versus Non–Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease. American Journal of Cardiology, 2010, 105, 786-791.	1.6	5
87	Delays in antiâ€hyperglycaemic therapy initiation and intensification are associated with cardiovascular events, hospitalizations for heart failure and allâ€cause mortality. Diabetes, Obesity and Metabolism, 2019, 21, 1551-1557.	4.4	5
88	The association between heart failure hospitalization and self-reported domains of health. Quality of Life Research, 2020, 29, 953-958.	3.1	1
89	Confirming diagnoses of acute pancreatitis with commonly available electronic data. Pharmacoepidemiology and Drug Safety, 2021, 30, 313-319.	1.9	1
90	Impact of Implementing Glycated Hemoglobin Testing for Identification of Dysglycemia in Youth., 2014, 18, 21-27.		1

#	Article	lF	CITATIONS
91	The epidemiology of congestive heart failure in hyperglycemia below the threshold for diabetes: A critical review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2007, 1, 273-278.	3.6	0
92	Response to Olivarius and Siersma: Weight change or change in weight trend. Differences in analytical approaches (and differences in study samples). Diabetes, Obesity and Metabolism, 2007, 10, 070506175719001-???.	4.4	0
93	Reply. American Journal of Cardiology, 2015, 116, 1486.	1.6	0
94	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0